CHIMERIC VACCINE ANTIGEN WITH TRIPLE ACTION AGAINST CANINE EHRLICHIOSIS, ANAPLASMOSIS AND BABESIOSIS, EXPRESSION VECTOR, RECOMBINANT CELL, VACCINE COMPOSITION, DIAGNOSTIC KIT, TREATMENT METHOD AND USE OF CHIMERIC PROTEIN

Abstract

The present invention relates to the development of vaccine formulations obtained from a recombinant chimeric protein (rTripEAB) with CD8+ and CD4+ T cell epitopes, optimized using bioinformatics tools, whose sequence contains conserved regions. The invention also relates to the composition of the vaccine formulation with the chimeric antigen in conjunction with adjuvants, as well as to the evaluation of its protective efficacy against infection by Ehrlichia canis, Anaplasma platys, and Babesia canis. The technology is directly applicable for the protection against infectious diseases in dogs, swine, cattle, horses, and humans, directly impacting the health and well-being of individuals.